A recent study found that the titre of stimulatory anti-AT1R antibodies decreased after HSCT in patients with SSc, whereas their reactivity was not influenced by the treatment [109], suggesting that HSCT may not be effective in improving overall anti-GPCR-mediated manifestations. The gene discussed is AGTR1; the disease is systemic sclerosis.